GSK (GSK) shares rose in early trading on Tuesday after the US Food and Drug Administration published documents related to a potential approval of the company's blood cancer drug, Bloomberg reported.
The FDA's Oncologic Drugs Advisory Committee is scheduled to meet on Thursday to discuss GSK's Blenrep, Bloomberg reported, adding that a decision on approval of the drug is expected by July 23.
Blenrep has been approved in the UK in combination with other oncology drugs to treat certain patients with multiple myeloma, an incurable blood cancer, Bloomberg reported.
GSK shares were 0.7% higher in recent trading.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: 38.54, Change: +0.24, Percent Change: +0.63
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。